Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

AcneFeatured ArticlesJDD HighlightsJDD in the MediaThe Latest
February 13, 2024

JDD in the News: Topical Clascoterone Efficacy Increases Over Time for Acne

by Allison Sit Dermatology Advisor, Dermatology News, Healio, Medriva and Medscape all covered a Journal of Drugs in Dermatology study about the long-term safety and effectiveness of topical clascoterone for…
Featured ArticlesJDD HighlightsJDD in the MediaThe Latest
January 16, 2024

JDD in the News: Combination Therapy for Non-Melanoma Skin Cancer

by Allison Sit The Journal of Drugs in Dermatology made news in Healio recently with several articles including one about a combination therapy for non-melanoma skin cancer. The study, “Cryosurgery…
Featured ArticlesJDD HighlightsJDD in the MediaThe Latest
December 21, 2023

JDD in the News: Telemedicine Trends

by Allison Sit Healio wrote about a recent Journal of Drugs in Dermatology study on telehealth usage from a physician’s perspective. The study, “Telemedicine Versus Teledermatology Usage and Perception Among…

Leave a Reply